At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 97 enrolled
Drug / intervention
GSK1120212drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated With or Without a BRAF Inhibitor
In Brief
A Phase 2 clinical trial evaluating GSK1120212 for Cancer. Completed, enrolled 97 participants across 10 sites in 2 countries.
Detailed Summary
MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or without a BRAF inhibitor. GSK1120212 is a potent and highly selective inhibitor of MEK activation and kinase activity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesAustralia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedDec 2009
Primary CompletionJul 2011
Study CompletionJan 2013
TodayJul 2026
First PostedDec 21, 2009
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2011
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.5 years ago
Interventions
GSK1120212drug
Daily oral dosing